BioTime to Present at Two Upcoming Investor Conferences
May 20 2016 - 5:08PM
Business Wire
BioTime, Inc. (NYSE MKT and TASE: BTX) announced that Co-Chief
Executive Officer Michael D. West, Ph.D., will present at the 2016
Oppenheimer 17th Annual Israel Conference to be held at the David
Intercontinental Hotel in Tel-Aviv on Sunday, May 22, 2016.
Dr. West will also present at the Mauldin Economics 2016
Strategic Investment Conference, in Dallas, Texas on May 25, 2016.
The conference features innovative companies with its theme titled
“Decade of Disruption.”
Michael West, Ph.D., will be sharing his knowledge as an
industry leader and authority in pluripotent stem cells and
regenerative medicine, with a particular focus on BioTime’s
strategy to lead in the application of the technology in the large
and growing markets in age-related degenerative disease. Dr. West
will also be participating in two panel discussions to discuss his
views on future trends in business and technology.
Panel discussion times will be:Wednesday, May 25th - 3:20pm -
4:10pmThursday, May 26th - 3:55pm - 4:45pm
More information is available at
www.mauldineconomics.com/sic-2016 and the
presentations will be made available on the BioTime
website in the Investor’s section under Events &
Presentations.
About BioTime
BioTime, Inc. is a clinical-stage biotechnology company focused
on developing and commercializing novel therapies developed from
what we believe to be the world’s premier collection of pluripotent
cell assets. The foundation of our core therapeutic technology
platform is pluripotent cells that are capable of becoming any of
the cell types in the human body. Pluripotent cells have potential
application in many areas of medicine with large unmet patient
needs, including various age-related degenerative diseases and
degenerative conditions for which there presently are no cures.
Unlike pharmaceuticals that require a molecular target, therapeutic
strategies based on the use of pluripotent cells are generally
aimed at regenerating or replacing affected cells and tissues, and
therefore may have broader applicability than pharmaceutical
products.
In addition to the development of therapeutics, BioTime’s
research and other activities have resulted, over time, in the
creation of other subsidiaries that address other non-therapeutic
market opportunities such as cancer diagnostics, drug development
and cell research products, and mobile health software
applications.
BioTime common stock is traded on the NYSE MKT and TASE under
the symbol BTX. For more information, please visit
www.biotimeinc.com or connect with the company on Twitter,
LinkedIn, Facebook, YouTube, and Google+.
FORWARD-LOOKING STATEMENTS
Statements pertaining to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for BioTime and its
subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to
statements that contain words such as “will,” “believes,” “plans,”
“anticipates,” “expects,” “estimates”) should also be considered to
be forward-looking statements. Forward-looking statements involve
risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the business of BioTime and
its subsidiaries, particularly those mentioned in the cautionary
statements found in BioTime's Securities and Exchange Commission
filings. BioTime disclaims any intent or obligation to update these
forward-looking statements.
To receive ongoing BioTime corporate communications, please
click on the following link to join our email alert list:
http://news.biotimeinc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160520005916/en/
BioTime, Inc.Dan L. Lawrence,
510-775-0510dlawrence@biotimeinc.comorInvestor Contact:EVC Group,
Inc.Michael Polyviou, 646-445-4800mpolyviou@evcgroup.comorMedia
Contact:Gotham Communications, LLCBill Douglass,
646-504-0890bill@gothamcomm.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Sep 2023 to Sep 2024